CAMBRIDGE, Mass., Jan. 10, 2022 /PRNewswire/ -- Akebia
Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company
with the purpose to better the lives of people impacted by kidney
disease, today announced that David
Spellman, Chief Financial Officer, will participate in a
fireside chat at the H.C. Wainwright Bioconnect Conference, which
will take place virtually January 10-13,
2022.
An audio replay of the fireside chat will be available through
the Investors section of Akebia's website at
https://ir.akebia.com for approximately 90 days following the
conference.
About Akebia Therapeutics
Akebia Therapeutics, Inc. is
a fully integrated biopharmaceutical company with the purpose to
better the lives of people impacted by kidney disease. Akebia was
founded in 2007 and is headquartered in Cambridge, Massachusetts. For more
information, please visit our website at www.akebia.com, which does
not form a part of this release.
Akebia Therapeutics Contact
Mercedes Carrasco
Mcarrasco@akebia.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/akebia-therapeutics-to-present-at-hc-wainwright-bioconnect-conference-301456833.html
SOURCE Akebia Therapeutics